Clinical Trial Update: Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update comparing two-dose versus three-dose regimens of Heplisav-B in patients with cirrhosis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hepatitis B
• Liver Disease

Drugs mentioned

• HEPLISAV-B (hepatitis B vaccine, adjuvanted)

Snippet

Sponsor: Mercy Medical Center | Conditions: Hepatitis B, Cirrhosis, Liver | Phase 4 | Status: RECRUITING